1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

  • May 2019
  • 232 pages
  • ID: 5778930
  • Format: PDF
  • By BCC Research

Summary

Table of Contents

Report Scope:
The scope of this report is broad and covers type, production method, technology and applications of radiopharmaceuticals and therapeutics.By type, the market has been segmented into radiotherapy and radiopharmaceuticals.

Revenue forecasts from 2017 to 2023 are provided for each segment and regional market, with estimated values derived from manufacturers’ total revenues.

The report also includes a discussion of the major players in each region in the radiopharmaceutical and therapeutics market. Further, it explains the major drivers and regional dynamics of the global radiopharmaceutical and therapeutics market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and detailed profiles of the major vendors in this market.

Report Includes:
- 94 data tables and 83 additional tables
- An overview of the global market for radiotherapy, radiopharmaceuticals and nuclear medicines
- Examination of present and future strategies within the radiopharmaceuticals market, including radiopharmaceuticals for both diagnostic and therapeutic purposes
- Detailed description of positron emission tomography (PET) and single photon emission computed tomography (SPECT) and discussion of their applications
- Evaluation of market opportunities for external beam radiation therapy, internal radiation therapy and systemic radiotherapy
- Coverage of new products launches and product enhancement in the industry
- Comprehensive company profiles of major players, including Accuray Inc., Bayer Pharma AG, C. R. Bard Inc., Eli Lilly and Company, Navidea Biopharmaceuticals Inc., Siemens Healthcare, and Triad Isotopes Inc.

Summary
Population and human life expectancy are growing globally, spurring more chronic conditions and lifethreatening diseases.Obesity, a sedentary lifestyle and a lack of physical activity have further worsened the situation, leading to the increased importance of medical interventions and treatments.

Despite incredible advancements in the field of medicine in the last few decades, an unmet need remains for the prevention, diagnosis and treatment of aggressive ailments such as cancer, cardiovascular diseases and central nervous system disorders.

Since the discovery of radioactivity, it has been recognized that radiation can play a role in the treatment of various diseases.Radiopharmaceuticals are a type of radioactive drug that is internally administered and intended for use in the diagnosis and treatment of diseases.

Radiopharmaceuticals are now a crucial part of the healthcare industry, as they can identify various disease processes much earlier than other diagnostic tests.Applications of radiopharmaceuticals are growing significantly in the fields of cardiology, neurology, oncology and other medical specialties such as endocrinology, gastroenterology and nephrology, for both diagnostic and therapeutic purposes.

Radiopharmaceuticals have also become an inevitable part of personalized medicine.Diagnostic applications account for morethan an REDACTED share of the global radiopharmaceutical market, and therapeutic applications constitutethe smaller part of the market.

The market for therapeutic radiopharmaceuticals is expected to grow atsteep rate in the coming years, due to growing applications and increased demand.

Growing acceptance and utilization of nuclear medicine scans (i.e., SPECT and PET) and better availability of radiopharmaceuticals due to an increasing number of cyclotrons have significantly contributed to growth in the radiopharmaceutical industry. Innovative technological equipment leading to early and accurate diagnoses, increased awareness of radiopharmaceuticals among physicians and patients and new regulatory approvals of radiopharmaceuticals are other major driving forces for the global radiopharmaceutical market. Furthermore, increasing incidences of different types of cancers across the globe are considered a major driver behind the growth of radiopharmaceuticals and therapeutics. According to Our World in Data, approximately 19 million people had cancer in 1990; that has increased more than two-fold as of 2016, reaching 42 million worldwide. In addition, breast cancer
has been identified as the leading type of cancer, as eight million people had breast cancer in 2016. In the same year, 6.3 million, 5.7 million and 2.8 million people had colon and rectum cancer, prostate cancer and tracheal, bronchus and lung cancer, respectively. Hence, the increasing incidences of various cancers drives the need for radiopharmaceuticals and therapeutics, considering diagnostic and therapeutic areas.

The global radiopharmaceutical and therapeutics market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach more than REDACTED, an increase of REDACTED from the REDACTED in revenue in 2017.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($5500)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dyslipidemia - Pipeline Review, H2 2019

Dyslipidemia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Dyslipidemia - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2019, provides an overview of the Dyslipidemia (Metabolic ...

Actinic (Solar) Keratosis - Pipeline Review, H2 2019

Actinic (Solar) Keratosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Actinic (Solar) Keratosis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Pipeline Review, H2 2019, provides an overview of ...

Pruritus - Pipeline Review, H2 2019

Pruritus - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Pruritus - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H2 2019, provides an overview of the Pruritus (Dermatology) pipeline ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on